Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Glenn J. Bubley, M.D.

Co-Author

This page shows the publications co-authored by Glenn Bubley and Meredith Regan.
Connection Strength

0.642
  1. Dramatic and prolonged PSA response after retreatment with a PSA vaccine. Clin Genitourin Cancer. 2013 Sep; 11(3):362-4.
    View in: PubMed
    Score: 0.135
  2. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006 Dec 01; 24(34):5408-13.
    View in: PubMed
    Score: 0.086
  3. Chemo-hormonal therapy for biochemical progression of prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4559.
    View in: PubMed
    Score: 0.083
  4. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004 Feb; 63(2):327-32.
    View in: PubMed
    Score: 0.071
  5. Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res. 2003 Aug 15; 9(9):3282-7.
    View in: PubMed
    Score: 0.068
  6. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. J Urol. 2002 Nov; 168(5):2249-52.
    View in: PubMed
    Score: 0.065
  7. Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4657.
    View in: PubMed
    Score: 0.029
  8. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011 Feb; 185(2):471-6.
    View in: PubMed
    Score: 0.028
  9. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.
    View in: PubMed
    Score: 0.026
  10. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology. 2009 Nov; 74(5):1156-61.
    View in: PubMed
    Score: 0.026
  11. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.